Life science technology company 10x Genomics Inc (Nasdaq:TXG) on Wednesday announced a research collaboration with Lausanne University Hospital (CHUV), a Swiss academic medical centre, to advance research in diagnostic applications of single cell and spatial technologies for cancer care.

This collaboration builds on 10x's broader efforts to work with leading research institutions to generate the scientific evidence needed to advance future diagnostic applications of single cell and spatial technologies.

The study is planned to use 10x's Flex Apex and Xenium platforms, with the goal of expanding to the Atera platform, to examine tumour samples from patients with advanced cancer undergoing a comprehensive evaluation by a clinical molecular tumour board. The research aims to identify clinically relevant biomarkers that may help predict treatment response, cancer prognosis and support diagnostic development.

Hundreds of patients are expected to take part in the study across multiple solid tumour types, including non-small cell lung cancer, breast cancer, bladder cancer and melanoma. Researchers plan to integrate single cell and spatial biology with clinical outcomes data to better understand mechanisms of response and resistance across a range of therapeutic approaches, including antibody-drug conjugates, bispecific antibodies and immune checkpoint inhibitors. The collaboration will also investigate how 10x single cell and spatial technologies can be deployed clinically alongside current standard-of-care assays.

10X expects the collaboration to generate a comprehensive, multimodal resource integrating single cell and spatial data to enable the discovery of clinically actionable biomarkers of treatment response and resistance. It also plans to evaluate how these biomarkers could be incorporated into future clinical reporting frameworks to support personalised treatment planning and molecular tumour board decision-making.